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Abstract
Background: The usefulness of sputum Gram stain in patients with community-acquired pneumonia (CAP) is
controversial. There has been no study to evaluate the diagnostic value of this method in patients with
healthcare-associated pneumonia (HCAP). The purpose of this study was to evaluate the usefulness of sputum
Gram stain in etiological diagnosis and pathogen-targeted antibiotic treatment of CAP and HCAP.
Methods: We conducted a prospective observational study on hospitalized patients with pneumonia admitted to our
hospital from August 2010 to July 2012. Before administering antibiotics on admission, Gram stain was performed and
examined by trained physicians immediately after sputum samples were obtained. We analyzed the quality of sputum
samples and the diagnostic performance of Gram stain. We also compared pathogen-targeted antibiotic treatment
guided by sputum Gram stain with empirical treatment.
Results: Of 670 patients with pneumonia, 328 were CAP and 342 were HCAP. Sputum samples were obtained from
591 patients, of these 478 samples were good quality. The sensitivity and specificity of sputum Gram stain were 62.5%
and 91.5% for Streptococcus pneumoniae, 60.9% and 95.1% for Haemophilus influenzae, 68.2% and 96.1% for Moraxella
catarrhalis, 39.5% and 98.2% for Klebsiella pneumoniae, 22.2% and 99.8% for Pseudomonas aeruginosa, 9.1% and 100%
for Staphylococcus aureus. The diagnostic yield decreased in patients who had received antibiotics or patients with
suspected aspiration pneumonia. Pathogen-targeted treatment provided similar efficacy with a decrease in adverse
events compared to empirical treatment.
Conclusions: Sputum Gram stain is highly specific for the etiologic diagnosis and useful in guiding pathogen-targeted
antibiotic treatment of CAP and HCAP.
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Background
The sputum Grain stain is a simple and inexpensive
method for the rapid diagnosis of microbial etiologies of
pneumonia. However, the usefulness of sputum Gram
stain in the initial approach to patients with community-
acquired pneumonia (CAP) is still controversial. Some
studies have had doubt on the usefulness of sputum
Gram stain in terms of difficulty to obtain good quality
samples, sensitivity, reliability, and overall impact on
treatment decisions [1-3]. Guidelines do not recommend
routine sputum Gram stain on patients with CAP [4-7].
The Japanese Respiratory Society (JRS) guidelines rec-
ommends pathogen-specific treatment using rapid diag-
nostic methods such as sputum Gram stain if possible
[8]. However, this treatment strategy has not been
validated.
Healthcare-associated pneumonia (HCAP) is a rela-
tively new category of pneumonia proposed by the 2005
American Thoracic Society (ATS)/Infectious Diseases
Society of America (IDSA) guidelines [9]. HCAP is distinct
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from CAP because which has risk factors for multidrug-
resistant (MDR) pathogens that often carry a poor
prognosis. Thus far no study has evaluated the useful-
ness of sputum Gram stain in patients with HCAP.
We therefore conducted a prospective study to assess
the usefulness of sputum Gram stain on hospitalized pa-
tients with CAP and HCAP. Primary objective of our
study was the diagnostic performance of sputum Gram
stain. The secondary objective was to assess the effect-
iveness of the initial antibiotic treatment guided by
sputum Gram stain.
Methods
We conducted a prospective observational study of con-
secutive patients with pneumonia who were hospitalized
at Okinawa Chubu Hospital (a 550-bed acute care hos-
pital in Okinawa, Japan) from August 2010 to July 2012.
Pneumonia was defined as a new infiltrate on chest
X-ray together with signs and symptoms of a lower
respiratory tract infection: fever, cough, sputum, dyspnea,
chest pain. We excluded patients if they were considered
at follow up to have other diseases that distinguished them
from pneumonia. Sputum Gram stain was performed and
interpreted by trained physicians in the emergency room
on admission. We analyzed the diagnostic performance
of the sputum Gram stain. We also compared pathogen-
targeted antibiotic treatment guided by sputum Gram
stain with empirical treatment. This study was approved
by ethics committee of Okinawa Chubu Hospital. Sputum
samples were collected as part of standard patient care
and as this was an observational study, written informed
consent was deemed unnecessary.
Data collection
We collected data on age, sex, onset location, social his-
tory, co-morbid conditions, medications, results of labora-
tory testing, and chest radiographs. We calculated the
Pneumonia Severity Index (PSI) of the Patient Outcomes
Research Team (PORT score) at admission [10]. We re-
corded any initial treatment failure, any adverse event of
the initial antibiotics, need for intensive care unit (ICU)
admission, durations of intravenous antibiotic treatment,
length of hospital stay, and in-hospital mortality.
Sputum evaluation
Expectorated sputum samples were collected before ad-
ministering antibiotics. Nasotracheal suctioned sputum
samples were collected by the attending nurse from
the patients who could not expectorate due to altered
mental status. The Gram stain was performed and
interpreted by trained resident physicians (Post-graduate
year 1 or 2) as soon as possible after the sputum samples
were obtained. Sputum samples were considered of good
quality if they had <10 squamous epithelial cells (SECs)
per low-power field (LPF) and >10 polymorphonuclear
leukocytes (PMNs) per oil immersion field (OIF). Other
samples were excluded from the evaluation. In good
quality samples, >10 microorganisms of same morpho-
type at OIF were considered as meaningful. The presence
of many morphologic microorganisms which a predomin-
ant morphotype was not identified was considered as poly-
microbial flora. Morphotypes and the presumptive bacteria
were following (Figure 1): Gram-positive lancet-shaped
diplococci (GPDC) for Streptococcus pneumoniae, Gram-
negative coccobacilli (GNCB) for Haemophilus influenzae,
Gram-negative diplococci (GNDC) for Moraxella catar-
rhalis, Gram-negative rods large sized (GNR-large) for
Klebsiella pneumoniae, Gram-negative rods small sized
(GNR-small) for Pseudomonas aeruginosa, Gram-positive
cocci in clusters (GPC-cluster) for Staphylococcus aureus.
Reference standard
There is no universally accepted gold standard for asses-
sing the diagnostic value of sputum Gram stain. Previous
studies used the sputum culture or blood culture. Al-
though sputum culture is most commonly used refer-
ence standard, it lacks both sensitivity and specificity
[11,12]. Blood culture is highly specific but poorly sensi-
tive [13,14]. Some authors reported that investigation of
sputum by a combination of Gram stain, culture, and
detection pneumococcal antigen was the most useful
means of establishing an aetiological diagnosis of CAP
[15]. In our study, the combination of multiple diagnos-
tic methodologies was used as reference standard be-
cause we consider it reliable. An etiological diagnosis
was considered presumptive if any of the following
criteria were fulfilled: 1) moderate to heavy growth from
semiquantitative sputum culture; 2) positive culture in
bronchoalveolar lavage or pleural fluid; 3) positive blood
culture if no other source was identified; 4) positive
urinary antigen test for S. pneumoniae. Two sets of blood
cultures were performed before administering antibiotics
in all patients. Bronchoalveolar lavage samples or pleural
fluid samples were collected when clinically indicated.
Definitions
Patients with pneumonia were classified into CAP and
HCAP. HCAP included any patients who was 1) hospi-
talized in an acute care hospital for two or more days
within the past 90 days, 2) resided in a nursing home or
long-term care facility, 3) received recent intravenous
antibiotic therapy, chemotherapy, or wound care within
the past 30 days, 4) attended a hospital or hemodialysis
clinic [9]. Patients were classified into CAP if they did
not meet the criteria for HCAP.
Patients were defined as being immunosuppressed if they
had more than one of the following risk factors: 1) daily ad-
ministration of systemic corticosteroids (at least 10 mg per
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day of prednisone or an equivalent drug); 2) administration
of an immunosuppressive drug; 3) received cancer chemo-
therapy within the past 30 days; 4) recipient of transplant-
ation (bone marrow or solid organ); 5) underlying
congenital or acquired immune deficiency disorder.
The diagnosis of aspiration pneumonia was made based
on the JRS guidelines for the management of hospital-
acquired pneumonia [16]: overt aspiration (apparent
aspiration), a condition in which aspiration was strongly
suspected, or the existence of abnormal swallowing
function or dysphagia. In addition, we carried out water
swallowing tests or videoendoscopy for the purpose of
swallowing function evaluation in suspected cases.
The initial antibiotic treatment was considered as
being pathogen-targeted if ampicillin was prescribed to a
patient with GPDC (S. pneumoniae) on the Gram stain,
a third-generation cephalosporin was prescribed to a
patient with GNCB (H. influenzae), ampicillin-sulbactam
was prescribed to a patient with GNDC (M. catarrhalis),
a second or third-generation cephalosporin was pre-
scribed to a patient with GNR-large (K. pneumoniae), an
antipseudomonal agent was prescribed to a patient with
GNR-small (P. aeruginosa), and vancomycin was pre-
scribed to a patient with GPC-cluster (S. aureus).
Statistical analysis
For the comparisons between groups, we used the χ2 or
Fisher exact test for categorical variables and Mann–
Whitney U test for continuous variables. Statistical sig-




S. pneumoniae S. aureus
H. influenzae M. catarrhalis
K. pneumoniae P. aeruginosa
Figure 1 Bacterial morphotypes in sputum Gram stain (×100, oil immersion field). Gram positive diplococci (lancet-shaped or football-shaped)
are suggestive of Streptococcus pneumoniae (A). Cluster of Gram positive cocci are suggestive of Staphylococcus aureus (B). Tiny Gram negative
coccobacilli are suggestive of Haemophilus influenzae (C). Gram negative diplococci (kidney bean-shaped) are suggestive of Moraxella catarrhalis (D).
Plump Gram negative rods are suggestive of Klebsiella pneumoniae (E). Thin gram negative rods are suggestive of Pseudomonas aeruginosa (F).
Fukuyama et al. BMC Infectious Diseases 2014, 14:534 Page 3 of 8
http://www.biomedcentral.com/1471-2334/14/534
sputum Gram stain was evaluated compared with refer-
ence standard. Diagnostic parameters such as sensitivity,
specificity, and positive predictive value (PPV) and nega-
tive predictive value (NPV) were calculated. All data
were analyzed and processed on Stata 11® (StataCorp,
College Station, TX, USA).
Results
Characteristics of patients
The characteristics of patients with CAP and HCAP
are listed in Table 1. A total of 670 patients with pneu-
monia were enrolled in this study. Of these, 328 had
CAP and 342 had HCAP. The median age was 77 years
(interquartile range (IQR) 65–85 years). Six hundred
thirty five patients (94.8%) had at least one underlying
disease; chronic lung disease 301, chronic heart disease
152, chronic liver disease 21, chronic kidney disease 55,
cerebrovascular disease 180, neuromuscular disease 64,
cancer 58, collagen vascular disease 15, dementia 97, dia-
betes mellitus 128, hypertension 305, and hyperlipidemia
92. An etiological diagnosis was established in 417 (62.2%)
of 670 patients. S. pneumoniae was the most frequent
causative pathogen in both CAP and HCAP.
Sputum samples evaluation
As shown in Figure 2 and Table 2, sputum samples were
obtained from 591 patients. Of the samples, 478 were
considered of good quality. Two hundred seventy one
showed a predominant morphotype, 150 showed polymi-
crobial flora, and 57 showed no meaningful microorgan-
isms. In patients who had received antibiotics before
admission, the sputum samples showed no meaningful
microorganism more frequently (24.7 vs 5.8%, p < 0.0001)
and lower diagnostic yield (13.4 vs 30.7%, p = 0.0005) than
those who had not. In patients with suspected aspiration
pneumonia, sputum samples showed polymicrobial flora
more frequently (33.7 vs 15.8%, p < 0.0001) with a lower
diagnostic yield (20.7 vs 32.5%, p = 0.0011) than those
without aspiration.
Predictive accuracy for the etiologic diagnosis
Table 3 shows the predictive performance of sputum
Gram stain according to predominant morphotype. The
sensitivity and specificity of sputum Gram stain were
62.5% and 91.5% for S. pneumoniae, 60.9% and 95.1%
for H. influenzae, 68.2% and 96.1% for M. catarrhalis,
39.5% and 98.2% for K. pneumoniae, 22.2% and 99.8%
for P. aeruginosa, 9.1% and 100% for S. aureus.
Diagnostic value in patients with HCAP
Table 4 shows the diagnostic performance of sputum
Gram stain in patients with CAP and HCAP. The diag-
nostic yield in HCAP patients was lower than that in
CAP patients (24.0 vs 32.6%, p = 0.0129). The specificity
for the etiologic diagnosis was high in both CAP and
HCAP. The sensitivity for the etiologic diagnosis in
HCAP was lower than that in CAP.
Pathogen-targeted treatment and empirical treatment
Comparison between pathogen-targeted treatment and
empirical treatment is shown in Table 5. Among the 271
patients with a predominant morphotype, 174 patients
received pathogen-targeted initial antibiotic treatment.
Severity scores were higher in patients who received em-
pirical treatment than in patients who received pathogen-
targeted treatment. There was no significant difference
regarding the frequency of initial antibiotic treatment
failure and in-hospital mortality between the two groups.
The frequency of adverse events was significantly lower
in patients who received pathogen-targeted treatment
Table 1 Characteristics of patients with CAP and HCAP
All patients CAP HCAP
n = 670 n = 328 n = 342
Patient background
Age, median (IQR) 77 (65–80) 75 (59–83) 80 (72–87)
Male, n (%) 430 (64.2) 212 (64.6) 218 (63.7)
Comorbid conditions, n (%) 635 (94.8) 296 (90.2) 339 (99.1)
Previous antibiotics treatment,
n (%)
97 (14.5) 34 (10.4) 63 (18.4)
Immunosuppressed, n (%) 40 (6.0) 19 (5.8) 21 (6.1)
Suspected aspiration, n (%) 246 (36.7) 50 (15.2) 196 (57.3)
Severity scores
PSI score, median (IQR) 110 (89–140) 96 (73–120) 125 (104–153)
PSI class, median (IQR) 4 (3–5) 4 (3–4) 4 (4–5)
Clinical outcomes
Initial treatment failure, n (%) 78 (11.6) 28 (8.5) 50 (14.6)
Antibiotics adverse effect, n (%) 40 (6.0) 19 (5.8) 21 (6.1)
ICU admission, n (%) 81 (12.1) 41 (12.5) 40 (11.7)
Length of antibiotic treatment,
median (IQR)
8 (6–11) 7 (6–10) 9 (7–13)
Length of hospital stay,
median (IQR)
11 (8–19) 9 (7–16) 12 (9–22)
In-hospital mortality, n (%) 59 (8.8) 19 (5.8) 30 (8.8)
Pathogen identified, n (%) 417 (62.2) 206 (62.8) 211 (61.7)
Streptococcus pneumoniae, n (%) 139 (20.7) 76 (23.2) 63 (18.4)
Haemophilus influenzae, n (%) 122 (18.2) 61 (18.6) 61 (17.8)
Moraxella catarrhalis, n (%) 41 (6.1) 20 (6.1) 21 (6.1)
Klebsiella pneumoniae, n (%) 43 (6.4) 11 (3.4) 32 (9.4)
Pseudomonas aeruginosa, n (%) 29 (4.3) 12 (3.7) 17 (5.0)
Staphylococcus aureus, n (%) 11 (1.6) 2 (0.6) 9 (2.6)
Mycoplasma pneumoniae, n (%) 10 (1.5) 9 (2.7) 1 (0.3)
Chlamydophila pneumoniae, n (%) 8 (1.2) 7 (1.0) 1 (0.3)
Legionella pneumophila, n (%) 2 (0.3) 0 2 (0.6)
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(2.9 vs 7.0%, p = 0.0492). The most frequent adverse
event was skin rash (n = 18), followed by pseudomem-
branous enterocolitis (n = 8), elevated liver enzymes
(n = 8), drug fever (n = 3), thrombocytopenia (n = 3).
Length of hospital stay and length of intravenous antibiotic
therapy were significantly longer in patients who received
empirical treatment.
Discussion
The usefulness of sputum Gram stain in patients with
CAP is controversial. While some authors have insisted
on the usefulness of sputum Gram stain [17-19], others
have argued for a limited value of this method [1-3]. The
diagnostic performance of sputum Gram stain in CAP
varies in different studies. The meta-analysis which eval-
uated the sputum Gram stain in community-acquired
pneumococcal pneumonia showed that the sensitivity
ranged 15-100% and specificity from 11-100% [20]. This
might be due to variations in study methodology. We
should take into account that the diagnostic yield of
sputum Gram stain depends on the reference standards,
the definitions of the positive Gram stain, and the popu-
lation of patients.
Some authors have pointed out that the limited value
of sputum Gram stain is due to the difficulty to obtain a
good quality sample [21,22]. In our study, a good quality
sputum samples was obtained in 478 (71.3%) of 670 pa-
tients, which is a higher yield than reported in previous
studies [21,22]. One reason for this is that we attempted
to collect not only expectorated sputum samples but
also nasotracheal suctioned sputum samples. We con-
sider it a reflection of our clinical practice that nasotra-
cheal suctioning from patients who could not cough up
sputum due to altered mental status was usually per-
formed. Another reason is the rapid collection and pro-
cessing of the sputum samples. Our hospital has a house
staff laboratory in the emergency room, and physicians
can perform Gram stain immediately after samples are
obtained. One study reported that good quality samples
had been obtained in only 20% of all patients, but the
Table 2 Sputum samples evaluation according to patient backgrounds
All patients Previous antibiotics Immunosuppressed Suspected aspiration
n = 670 n = 97 n = 40 n = 246
No sputum sample, n (%) 79 (11.8) 11 (11.3) 7 (17.5) 5 (2.0)
Poor quality sample, n (%) 113 (16.9) 20 (20.6) 9 (22.5) 54 (22.0)
Good quality sample, n (%) 478 (71.3) 66 (68.0) 24 (60.0) 187 (76.0)
No meaningful microorganism, n (%) 57 (8.5) 24 (24.7) 2 (5.0) 25 (10.2)
Polymicrobial flora, n (%) 150 (22.4) 16 (16.5) 4 (10.0) 83 (33.7)
Predominant morphotype, n (%) 271 (40.4) 26 (26.8) 18 (45.0) 79 (32.1)
Positive predict, n (%) 189 (28.2) 13 (13.4) 9 (22.5) 51 (20.7)
Figure 2 Results of sputum Gram stain in patients with CAP and HCAP.
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delay in collection and laboratory processing of the
samples was considerable [3]. The IDSA/ATS guidelines
recommends that Gram stain should be performed only
if quality performance measures for collection, transport,
and processing of samples can be met [4].
Previous studies reported that receiving antibiotics
before sputum sample collection adversely affect the
performance of Gram stain [3,18,22]. Our results also
demonstrated that previous antibiotic treatment de-
creased the diagnostic yield. Sputum samples without
identification of a meaningful microorganism were more
frequently obtained from patients who had received
antibiotics. In addition, we found that patients with sus-
pected aspiration pneumonia often showed polymicrobial
flora on sputum Gram stain more frequently and lower
diagnostic yield. Samples collected from patients with
aspiration pneumonia are often contaminated by the flora
of the oropharynx or upper airway.
The diagnostic value of sputum Gram stain for S. pneu-
moniae or H. influenzae was reported in many previous
studies [17-22]. However, other causative bacteria for
pneumonia can be estimated on sputum Gram stain. We
also investigated for S. aureus, M. catarrhalis, P. aerugi-
nosa, and K. pneumoniae in this study. The sputum Gram
stain was highly specific (>90%) for the diagnosis of the all
Table 4 Diagnostic performance of sputum Gram stain in
patients with CAP and HCAP
CAP HCAP p value
n = 328 n = 342
No sputum sample, n (%) 55 (16.8) 24 (7.0) <0.001
Poor quality sample, n (%) 43 (13.1) 70 (20.5) 0.011
Good quality sample, n (%) 230 (70.1) 248 (72.5) 0.49
No meaningful microorganism, n (%) 30 (9.1) 27 (7.9) 0.56
Polymicrobial flora, n (%) 56 (17.1) 94 (27.5) 0.001
Predominant morphotype, n (%) 144 (43.9) 127 (37.1) 0.0744
Positive predict, n (%) 107 (32.6) 82 (24.0) 0.013
Sensitivity (%)
Streptococcus pneumoniae 63.1 61.7
Haemophilus influenzae 76.8 44.4
Moraxella catarrhalis 85.0 54.2
Klebsiella pneumoniae 50.0 37.5
Pseudomonas aeruginosa 20.0 23.5
Staphylococcus aureus 50.0 0
Specificity (%)
Streptococcus pneumoniae 89.7 93.0
Haemophilus influenzae 94.8 95.3
Moraxella catarrhalis 97.6 92.4
Klebsiella pneumoniae 98.7 99.5
Pseudomonas aeruginosa 100 99.6
Staphylococcus aureus 100







n = 172 n = 498
Patient background
Age, median (IQR), y 80 (72–88) 76 (63–85) 0.064
Male, n (%) 90 (52.3) 340 (68.3) <0.001
Comorbid conditions, n (%) 163 (94.8) 472 (94.8) 0.157
CAP, n (%) 100 (58.1) 228 (45.8) 0.005
Previous antibiotics treatment,
n (%)
14 (8.1) 83 (16.7) 0.006
Immunosuppressed, n (%) 8 (4.7) 32 (6.4) 0.40
Suspected aspiration, n (%) 43 (25.0) 203 (40.8) <0.001
Severity scores
PSI score, median (IQR) 108 (89–128) 112 (90–142) 0.012
PSI class, median (IQR) 4 (3–4) 4 (4–5) 0.002
Clinical outcomes
Initial treatment failure, n (%) 13 (7.6) 61 (12.2) 0.091
Antibiotics adverse events,
n (%)
5 (2.9) 35 (7.0) 0.049
ICU admission, n (%) 12 (7.0) 69 (13.9) 0.017
Length of intravenous
treatment, median(IQR)
8 (6–9) 9 (7–13) <0.001
Length of hospital stay,
median (IQR)
9 (7–13) 11 (8–21) <0.001
In-hospital mortality, n (%) 14 (8.1) 45 (9.0) 0.72
Table 3 Predictive accuracy of sputum Gram stain for the etiologic diagnosis
Sensitivity Specificity PPV NPV LR (+) LR (−)
GPDC (Streptococcus pneumoniae) 62.5 (70/112) 91.5 (335/366) 69.3 (70/101) 88.9 (335/377) 7.38 0.41
GNCB (Haemophilus influenzae) 60.9 (67/110) 95.1 (350/368) 78.8 (67/85) 89.1 (350/393) 12.5 0.41
GNDC (Moraxella catarrhalis) 68.2 (30/44) 96.1 (417/434) 63.8 (30/47) 96.8 (417/431) 17.4 0.33
GNR-large (Klebsiella pneumoniae) 39.5 (15/38) 98.2 (432/436) 65.2 (15/23) 95.0 (432/455) 21.7 0.62
GNR-small (Pseudomonas aeruginosa) 22.2 (6/27) 99.8 (450/451) 85.7 (6/7) 95.5 (450/471) 100.2 0.78
GPC-cluster (Staphylococcus aureus) 9.1 (1/11) 100 (467/467) 100 (1/1) 97.1 (467/477) - 0.91
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bacteria. These results suggest that a positive sputum
Gram stain can lead to appropriate initial antibiotic
selection. On the contrary, the sensitivity varied in differ-
ent bacteria. The sensitivity for S. aureus, P. aeruginosa,
K. pneumoniae was low (9.1 to 39.5%). Failure to detect
these bacteria on sputum Gram stain does not mean the
absence.
To our knowledge, this is the first study to evaluate
the usefulness of sputum Gram stain in patients with
HCAP. Although the 2005 IDSA/ATS guidelines recom-
mended that all HCAP patients need broad-spectrum
antibiotic treatment [9], recent reports showed that this
approach is not appropriate because not all HCAP
patients had MDR pathogens [23,24]. The therapeutic
strategy for the appropriate initial antibiotic treatment
without overuse of broad-spectrum antibiotics in HCAP
patients is needed. We found the diagnostic yield of spu-
tum Gram stain in HCAP patients was lower than that
in CAP patients. The reason for this is that HCAP in-
cluded more patients with suspected aspiration pneumo-
nia. However, in good quality samples, the Gram stain
was highly specific (>90%) for the etiologic diagnosis in
HCAP patients. These results indicate that sputum
Gram stain is useful in guiding pathogen-targeted treat-
ment for HCAP patients.
Pathogen-targeted treatment guided by sputum Gram
stain provided similar efficacy with less frequent adverse
events than empirical treatment in this study. These re-
sults were similar to those of a randomized control trial
in which a pathogen directed approach was compared
with empirical treatment in patients with CAP [25]. Ad-
verse events of antibiotics often lead to poor outcomes
such as increased in-hospital mortality and longer length
of hospital stay. A recent study reported that empirical
treatment in concordance with the ATS/IDSA guidelines
was associated with increased mortality in hospital-
acquired pneumonia (HAP) and HCAP [26]. A potential
explanation could be antibiotic-specific adverse effect.
Additionally, the most important advantage of pathogen-
targeted treatment is a reduction in antimicrobial resist-
ance [27]. While there is no sufficient evidence of a
causative association between pathogen-targeted treat-
ment and antimicrobial resistance, there is little doubt
that appropriate antibiotic stewardship can reduce the
resistance. Physicians should make an effort to identify
the cause of pneumonia and avoid inappropriate overuse
of broad-spectrum antibiotics.
One of the notable features in our study method is
that the Gram stain was performed and interpreted by
physicians rather than laboratory technicians. Gram
staining by physicians is routine clinical practice in
our hospital. The resident physicians have been trained the
microbial examination as a part of our postgraduate med-
ical education. A benefit of Gram staining by physicians is
that they can check the quality of sputum samples and
the bacteria with their own eyes. The information is
useful for estimating causative bacteria in the initial ap-
proach, and often leads to pathogen-oriented treatment.
We found 174 of 271 (64.2%) patients with predominant
morphotype on Gram stain were treated with pathogen-
targeted treatment.
An additional benefit of sputum Gram stain is that it
can validate the subsequent sputum culture results [4].
The growth of an organism from a sputum sample does
not always indicate the presence of infection. Sputum
samples can become contaminated with saliva or upper
respiratory tract flora. Results of sputum culture can
yield false positive findings related to colonization or
contamination, and thus should be utilized with the
results of the sputum Gram stain when establishing the
definitive etiologic diagnosis of pneumonia.
There are several limitations to our study that should
be acknowledged. First, this is a single center study. Our
availability of Gram stain may not be applied to other
hospital settings. The performance of sputum Gram
stain is directory related to quality in the processing
of samples [3], and experience of the interpreters [28].
In many hospitals, microbiological examination is out-
sourced and few physicians perform Gram stain [29,30].
Second, atypical pathogens could not be fully evaluated.
Third, this is not a randomized control study to compare
pathogen-targeted treatment with empirical treatment.
Further study which evaluates the clinical efficacy of
pathogen-targeted treatment guided by sputum Gram
stain is needed.
Conclusion
In conclusion, sputum Gram stain is highly specific for
the etiologic diagnosis of CAP and HCAP and useful in
guiding pathogen-targeted antibiotic treatment.
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